Medpace Holdings, Inc. $MEDP Shares Sold by Ranger Investment Management L.P.

by · The Markets Daily

Ranger Investment Management L.P. reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 5.1% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 67,747 shares of the company’s stock after selling 3,665 shares during the quarter. Ranger Investment Management L.P.’s holdings in Medpace were worth $21,263,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of MEDP. Cim LLC lifted its position in Medpace by 5.9% during the second quarter. Cim LLC now owns 4,265 shares of the company’s stock valued at $1,339,000 after buying an additional 237 shares in the last quarter. Capital Impact Advisors LLC raised its stake in shares of Medpace by 1.9% in the 2nd quarter. Capital Impact Advisors LLC now owns 20,500 shares of the company’s stock valued at $6,498,000 after acquiring an additional 374 shares during the period. Nomura Holdings Inc. acquired a new position in shares of Medpace during the 2nd quarter valued at $408,000. Front Row Advisors LLC boosted its position in Medpace by 0.4% during the 2nd quarter. Front Row Advisors LLC now owns 9,441 shares of the company’s stock worth $2,963,000 after purchasing an additional 35 shares during the period. Finally, FORA Capital LLC increased its holdings in Medpace by 6.2% in the 2nd quarter. FORA Capital LLC now owns 5,141 shares of the company’s stock valued at $1,614,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In other news, CFO Kevin M. Brady sold 3,000 shares of the company’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $590.35, for a total value of $1,771,050.00. Following the sale, the chief financial officer owned 6,000 shares in the company, valued at approximately $3,542,100. This represents a 33.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 668 shares of the stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total transaction of $394,580.92. Following the transaction, the chief executive officer directly owned 646,184 shares in the company, valued at $381,694,426.96. The trade was a 0.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 387,925 shares of company stock valued at $233,386,647. Insiders own 20.30% of the company’s stock.

Medpace Stock Down 1.5%

Shares of MEDP opened at $557.90 on Friday. The firm has a market cap of $15.72 billion, a price-to-earnings ratio of 39.01, a PEG ratio of 2.10 and a beta of 1.43. The business’s 50 day moving average is $570.91 and its two-hundred day moving average is $462.80. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $626.26.

Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the company earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on MEDP shares. TD Cowen boosted their price objective on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research note on Friday, October 24th. BMO Capital Markets began coverage on Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price target for the company. Zacks Research upgraded shares of Medpace from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 27th. Robert W. Baird set a $613.00 target price on shares of Medpace in a research report on Friday, October 24th. Finally, Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, Medpace currently has a consensus rating of “Hold” and an average price target of $487.18.

Check Out Our Latest Stock Report on MEDP

Medpace Company Profile

(Free Report)

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Featured Stories

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).